Allergy and airway disease

Home · Topic library · Calendar

Browse: Drugs and biologics.

Status: active. Topic ID: allergy_airway. Evidence cutoff and last successful selective baseline check: September 13, 2026. Older studies below are baseline context, not new September findings.

Current state

Newly tracked WIN378 is testing longer-interval TSLP blockade in asthma and COPD. Early lung-function and biomarker signals do not establish fewer severe exacerbations or long-term safety. Registry and sponsor descriptions differ on phase and enrollment.

Questions to follow

• Food allergy: accidental-exposure protection, desensitization versus sustained unresponsiveness after stopping treatment, dietary freedom, quality of life, treatment burden, anaphylaxis and eosinophilic gastrointestinal disease. Follow biologics, oral/patch/sublingual immunotherapy and new human-stage approaches.
• Environmental allergy: symptom and medication reductions under ordinary seasonal/home exposure, including rhinitis, conjunctivitis and associated asthma. Keep challenge-chamber findings and skin-test changes separate from everyday benefit.
• Asthma/COPD: exacerbations, hospitalizations, oral-steroid exposure, breathing/function, lung-function decline, mortality, adherence and harms; specify eosinophils, smoking history and background inhalers rather than generalizing across phenotypes.
• Chronic sinus disease: congestion, smell, patient-reported function, steroid use, surgery decisions and recurrence. Separate disease with polyps from disease without polyps. Cross-link immunology with autoimmune therapies when appropriate.

Programs and next milestones

Focused update — 2026-11-10

Newly tracked long-acting anti-TSLP program separates early signals from exacerbation outcomes

Source date: 2026-11-09. Recorded in this review: November 10, 2026.

Evidence: Recovered human-program baseline and dated sponsor filing; earlier initiation dates retained.

Windward’s November 9 F-1/A describes anti-TSLP WIN378 POLARIS-1 Phase 2/3: 147 Phase 2 participants, interim first 98, and September 2026 Phase 3 initiation. Early FEV1/FeNO and half-life signals are sponsor evidence, not proof of fewer severe exacerbations or superiority to tezepelumab. No complete numerical harms table; sponsor reports no treatment-related serious events or discontinuations at its interim cutoff.

NCT07120503 still codes Phase 2 and planned 600 overall; sponsor describes approximately 600 additional Phase 3 participants. Retain these differences. Twice-yearly dosing is investigational.

Phase 2 week-24 results are forecast H1 2027 and week-48 H2 2027; Phase 3 H1 2029; POLARIS-2 enrollment H1 2027. SIRIUS COPD/NCT07646587 began June 2, 2026 (actual), plans 105, with H2 2027 sponsor topline and December 17, 2027 registry primary completion. No U.S. approval. Newly recovered program baseline, not November first dosing or definitive readout.

Next milestones: WIN378 POLARIS-1 Phase 2 week-24 results: 2027-H1 (Sponsor forecast November 9); WIN378 SIRIUS COPD topline and POLARIS-1 Phase 2 week-48 results: 2027-H2 (Sponsor forecast November 9); WIN378 POLARIS-1 and POLARIS-2 Phase 3 toplines: 2029-H1 (Sponsor forecast November 9).

Sources: Source 1; Source 2; Source 3.

Historical-source deduplication: The November 10 CT.gov lebrikizumab posting repeats primary adjusted oral-steroid contrasts already public in the EU results register on July 1, 2017: −6.5 points (95% CI −27.2 to 14.3) and −2.2 points (95% CI −20.7 to 16.3). The discontinued asthma study did not establish extra steroid sparing. Earlier termination and unequal safety-observation windows limit interpretation. No new scientific result event is added.

Coverage and remaining gaps: Reviewed the full saved topic corpus, scope and state. Retrieved all 122 ClinicalTrials.gov November 3–10 discovery records across two pages and all named records within 71 combined airway/infection IDs. Appraised original WIN378 filing, named protocols and selected regulator/sponsor/paper results. Worldwide appraisal back to the September overlap remains incomplete. Deduplicated lebrikizumab’s November 10 CT.gov posting against July 1, 2017 EU results: the primary adjusted contrasts were already public, with no demonstrated additional steroid sparing. No new result event added. Complete worldwide literature, non-U.S. registries, regulator and safety census and original audio/Q&A are unfinished. Do not advance full successful-check dates. WIN378 Phase 2/3 versus registry Phase 2 and sponsor additional versus registry overall enrollment remain unreconciled; no established severe-exacerbation benefit. Proactive e-consult COPD results require separate appraisal. GSK combination NCT07915791 remained not yet recruiting after the November 9 estimate.

Informal-source coverage: Targeted Viaskin, rademikibart, asthma/COPD Reddit and talk searches mainly returned known sponsor forecasts, patient accounts and an indexed October 21 Surya Bhatt interview discussing existing SEABREEZE data. No distinct new attributed claim was selected. Full recordings remain unappraised.

Full coverage record.

Focused update — 2026-11-06

Nasal mRNA therapy shows an early antiviral signal in asthma

Source date: 2026-11-05. Recorded in this review: November 6, 2026.

ETH47-201 (ISRCTN21576805) randomized 50 adults aged 18–65 with asthma on inhaled maintenance therapy to a single nasal ETH47 dose or placebo, one day before rhinovirus-A16 challenge; follow-up ran through day 42. ETH47 encodes interferon lambda. The sponsor reports 40-fold lower day-2 viral load, 14% lower peak lower-respiratory symptom score and 58% lower symptom-score AUC. It describes symptom, mild-exacerbation and medication changes as numerical trends; no primary-endpoint test, confidence intervals, exact arm denominators or dose amount are supplied.

The sponsor reports no severe/serious events after this single exposure. That does not establish uncommon or repeated-dose safety. High-interferon subgroup findings are exploratory. Controlled viral challenge and viral-load reductions do not establish prevention of severe real-world exacerbations, hospitalization or transmission. The registry confirms 50 participants but defers full details. Multiple-dose and asthma/COPD field trials are planned without dependable dates. ETH47 remains investigational.

Sources: Source 1; Source 2.

GSK registers a combination trial for COPD despite triple therapy

Source date: 2026-11-04. Recorded in this review: November 6, 2026.

NCT07915791 plans 279 adults aged 40–80 with moderate/severe COPD and exacerbations despite standard inhaled triple therapy. GSK3862995B plus GSK5784283 is compared with matching placebo on that background. Numerical doses are not disclosed. Primary outcome is annualized moderate/severe exacerbations in former smokers through 72 weeks; this is not simply a lung-function biomarker study.

Not yet recruiting, with November 9, 2026 estimated start, March 16, 2029 primary completion and February 15, 2030 final completion. No results or comparative safety are available; registration does not establish U.S. approval, efficacy of either component, or superiority over other biologics.

Sources: Source 1.

ENHANCE-3 records actual recruitment start

Source date: 2026-11-06. Recorded in this review: November 6, 2026. Related event date: 2026-11-02.

The ENHANCE-3 ensifentrine study (NCT07874815) changes from not yet recruiting with an October 23 estimate to recruiting with actual November 2, 2026 start. The saved large COPD exacerbation protocol and April 29, 2029 estimated completion remain distinct from completed ENHANCE studies. This closes an enrollment-status gap; it supplies no new exacerbation, mortality or comparative-harm result and does not establish a new indication.

Sources: Source 1.

Coverage and remaining gaps: focused_incomplete; ETH47 full protocol/publication and statistical primary-endpoint test deferred/unavailable. No full global food-allergy/asthma/CRS efficacy/safety appraisal; routine record-date changes do not establish new results.; Complete worldwide clinical, safety and informal-source appraisal remains unfinished; preserve prior full-success timestamps and baseline flags.

Informal-source coverage: Targeted asthma/COPD/allergy informal searches yielded publicity and patient discussion; no distinct new source-grounded rumor selected. ETH47 numerical trends remain sponsor evidence, not independent testimony. Full podcasts/talks remain unappraised.

Full coverage record.

Focused update — 2026-11-03

No additional finding was selected from the checked sources. Coverage remains incomplete; this is not a full-topic “no news” conclusion.

Related findings, recorded once: RESOLVE registers late-stage oral RSV treatment testing (source); FDA grants accelerated approval to VOCERYQ for adult recurrent respiratory papillomatosis (source); Dupilumab enters a mechanistic depression study (source).

Coverage and remaining gaps: focused_incomplete. No new fexlamose numerical harms tables recovered. Full ARNASA multiplicity and EPOPEX attrition/off-treatment benefit reconciliation incomplete. RhinAer/SWELL results first posted in 2024 and cannot be relabeled as new November efficacy. Cat registry retains older verification. Full global asthma/COPD/sinus/allergy appraisal unfinished.

Informal-source coverage: Targeted original patient/stock and sponsor searches did not select a distinct new development claim. No generic assumption of efficacy or safety from trial phase. Original long-form coverage remains partial.

Full coverage record.

Focused update — 2026-10-30

Fexlamose COPD trial misses efficacy endpoints and reports more respiratory harms

Source date: 2026-10-30. Recorded in this review: October 30, 2026.

Aer reports that AER-01-002 (NCT06731959) was a randomized study enrolling 119 adults with moderate-to-severe COPD, comparing nebulized fexlamose 90 mg daily or placebo for 28 days. More than 75% had severe/very severe airflow limitation. The study did not meet its primary or secondary efficacy endpoints: trough FEV1, FVC and other spirometry did not improve, and mucus-plug segment score did not show an overall baseline reduction.

Most respiratory adverse events, including COPD exacerbations, occurred with fexlamose; treatment discontinuation was much more frequent than with placebo. The announcement provides no arm denominators, effect estimates, confidence intervals or numerical harms/discontinuation rates. The magnitude cannot be reconstructed. This is a short sponsor topline, not an independent full report; it does not prove every mucolytic approach ineffective. Fexlamose remains investigational, with no U.S. approval established. Future program decisions and full tables have no verified date.

Next milestones: Full fexlamose tables and program decision: date unknown (No dependable date announced).

Sources: Source 1; Source 2.

ARNASA posts mixed dose comparisons and distinct safety denominators

Source date: 2026-10-28. Recorded in this review: October 30, 2026.

First posted results for NCT05595642 cover 1,380 randomized COPD participants: astegolimab 476 mg every two weeks, every four weeks or placebo. This is a separate trial from the previously appraised ALIENTO record. At 52 weeks, adjusted moderate/severe exacerbation rates were 1.000, 0.963 and 1.171 per participant-year (modified ITT n459/459/457). The two-week comparison was rate ratio 0.855 (95% CI 0.722–1.011), p=.0675; the four-week comparison 0.823 (0.695–0.975), p=.0239. The registry does not establish multiplicity-controlled success for the latter; the arm-level rate table also incorrectly attaches ratio intervals to rate values. Preserve the statistical comparison module rather than using those as rate intervals.

Safety is analyzed by treatment actually received after cross-arm dosing: n464/462/449. Serious events affected 113/124/107 and deaths 11/18/15, respectively. These are reported all-cause counts, not causally attributed drug deaths or proof of comparative mortality benefit. The prespecified overall TEAE outcome is marked not posted, although the adverse-event module is present. Detailed full-paper reconciliation remains needed. No new U.S. approval is established by posting; future regulatory timing is unverified.

Sources: Source 1.

Peanut-patch extension reports challenge responses with attrition and ongoing-treatment limits

Source date: 2026-10-28. Recorded in this review: October 30, 2026.

EPOPEX (NCT03859700) followed 304 EPITOPE completers: 205 previously assigned active patch and 99 previously assigned placebo, now all receiving daily DBV712 250 mcg. Challenge months are measured from the original EPITOPE baseline: at month 36, the switched group has approximately 24 months of active therapy. Response requires an eliciting (reaction-provoking) dose ≥1,000 mg when original baseline was >10 mg, or ≥300 mg when baseline was ≤10 mg; eliciting dose is not a tolerated dose. At the reported month-36 assessment, responder counts were 140/164 and 48/65 with available challenge data. Despite a title saying “percentage,” the structured values are counts. At month 48, only 54 switched-group participants have data (39 responders); the original-active denominator is zero. Missing follow-up is not treatment failure or proof of sustained protection.

All 205/99 participants had a treatment-related TEAE reported. Serious events occurred in 26/205 and 11/99; one per group was considered related to product, with no deaths. Systemic events of special interest affected 40/205 and 12/99. The specified outcome excludes accidental-ingestion events and challenge-related serious events. These are selected open-label, on-treatment observations, not an ongoing placebo comparison, free eating, cure or durable off-treatment remission. U.S. availability and ages remain indication-specific; this posting does not establish a new approval. Longer-term controlled/off-treatment results have no verified date.

Sources: Source 1.

AIRWARD registers a large COPD exacerbation trial

Source date: 2026-10-30. Recorded in this review: October 30, 2026.

Boehringer Ingelheim’s AIRWARD (NCT07907991) plans 1,800 adults aged ≥40 with symptomatic COPD, eosinophils <300/µL and frequent exacerbations despite usual therapy. Participants are randomized under quadruple masking to once-daily oral verducatib or matching placebo plus background care. The primary endpoint is annualized moderate/severe exacerbations through week 76; lung function, quality of life and safety are distinct secondary assessments.

The public record does not disclose a numerical tablet dose or establish human efficacy/safety. It is not yet recruiting: March 10, 2027 start, December 12, 2029 primary completion and January 9, 2030 final completion are estimates. This is investigational, not U.S. marketing approval; completion is not a promised public readout.

Next milestones: AIRWARD estimated start: 2027-03-10 (Registry estimate; not yet recruiting).

Sources: Source 1.

Dust-mite immunotherapy registrations share one protocol identifier

Source date: 2026-10-29. Recorded in this review: October 30, 2026.

NCT07904052 and NCT07904195 both describe MM09-SIT-063, EP-088_MM09 mannan-conjugated house-dust-mite allergoids. Each lists 250 participants aged 12–65, randomized masked active injection versus placebo, with a daily combined rhinitis/rhinoconjunctivitis symptom-and-medication score as primary outcome. They report different actual starts (February 24 and April 15, 2026), while otherwise sharing protocol identity. Do not add them into 500 unique participants or describe independent replication before sponsor reconciliation.

The records list recruiting, with July 2029 estimated completion, no results or new U.S. approval. Symptom/medication improvement is separate from skin-test change, anaphylaxis risk and sustained remission. The discrepancy and public-readout date remain unresolved.

Next milestones: MM09-SIT-063 reconciliation and results: date unknown (Protocol duplication and public results timing unresolved).

Sources: Source 1; Source 2.

Coverage and remaining gaps: focused_incomplete. No numerical fexlamose effect sizes/harms rates; full ARNASA multiplicity reconciliation, EPOPEX missingness/off-treatment benefit and actual first dosing of newly registered programs remain gaps. Complete worldwide appraisal unfinished.

Informal-source coverage: No distinct new original rumor promoted from patient/stock discussion. Two dust-mite registry records share a protocol ID and must not be counted as independent corroborating trials.

Full coverage record.

Focused update — 2026-10-27

PM647a prime-editing program enters the AAT-deficiency registry

Source date: 2026-10-21. Recorded in this review: October 27, 2026.

First posted October 21: NCT07887347 plans 54 participants in an open-label single-arm Phase 1/2 study of a single intravenous PM647a dose for homozygous PiZZ alpha-1 antitrypsin deficiency. Lung-phenotype and liver ± lung groups are separate. The brief mentions adolescents, but posted eligibility currently requires age ≥18; adolescent enrollment is not established.

The therapy aims to correct the SERPINA1 variant. Primary outcomes are adverse-event frequency/severity through 48 weeks; AAT levels, pulmonary function and selected liver-biopsy/stiffness measures are separate secondary outcomes. AAT normalization would not itself demonstrate preserved lung function or reduced liver morbidity.

U.S. status and timing: Investigational, not yet recruiting in the live registry; October 2026 remains an estimated start, not confirmed first dosing. Estimated primary completion December 2028 and final completion January 2029 retain month precision. No efficacy or safety results, actual launch or dependable public-readout date verified. Cross-linked to liver health.

Sources: Source 1.

PROSPERO extension misses its primary severe-exacerbation comparison

Source date: 2026-10-12. Recorded in this review: October 27, 2026.

Source date October 12; appraised October 27: PROSPERO (NCT05742802) extends tozorakimab follow-up after the earlier COPD trials. In the primary former-smoker population, severe-exacerbation rates across 104 weeks were 0.26 versus 0.33 per patient-year (annualized): rate ratio 0.79 (95% CI 0.61–1.01), p=.0587. The primary comparison was not statistically significant.

The overall former/current-smoker severe-exacerbation comparison was RR 0.73 (0.58–0.91), p=.0046; moderate/severe comparisons also favored treatment. Because the hierarchy stopped at the failed primary test, these are nominal secondary findings rather than a rescued positive primary endpoint. The extension randomized 1,713 selected completers of preceding studies; it is not a new unselected COPD population. The release does not provide adequate event counts/rates for a quantitative extension-specific adverse-event comparison. A sponsor statement of consistency cannot establish long-term safety.

U.S. status and timing: Investigational in the verified materials; previously announced Q1 2027 regulatory timing remains a sponsor forecast. This entry does not re-alert the earlier positive replicate-trial results or assume a scheduled CHEST talk was delivered. Detailed peer-reviewed extension tables and a confirmed FDA decision remain to follow.

Sources: Source 1; Source 2.

New toddler food-allergy protocols distinguish on-treatment desensitization from cure

Source date: 2026-10-27. Recorded in this review: October 27, 2026.

First posted October 27/26: Odense’s NCT07899359 plans 80 toddlers aged 0.5–3 years with challenge-confirmed allergy to a ten-food mixture, randomized to gradual multi-allergen oral immunotherapy or oat placebo. Its primary one-year challenge measures tolerance of 900 mg cumulative per food while treatment continues; additional challenge-negative groups are exploratory. Despite the title’s “curing” wording, this is not proof of durable off-treatment remission.

Aarhus/Randers NCT07895095 separately plans 56 infants/young children in an open-label randomized peanut-OIT versus avoidance comparison, with a 4,000 mg challenge at roughly 1–1.5 years. Designs and blinding differ and are not pooled. Neither trial has results or an established long-term safety advantage. These formal clinician-supervised research protocols do not authorize home desensitization or create a U.S. product approval.

Both are not yet recruiting. The first estimates January 1, 2027 start and December 2032 primary completion; the second retains October 2026 estimated start and October 2030 primary completion. Registration/start estimates are separate from actual first dosing and public readout dates.

Sources: Source 1; Source 2.

Coverage and remaining gaps: focused_partial. Bulk retrieval is not complete appraisal. Quantitative PROSPERO extension safety tables, actual PM647a first dose and a verified tozorakimab regulatory decision remain gaps.

Informal-source coverage: Patient discussions about existing asthma medicines are not development milestones. No distinct new original rumor selected; broader podcasts/talks remain incomplete.

Full coverage record.

Focused update — 2026-10-23

RO7830698 opens early COPD and healthy-volunteer recruitment

October 20 update — NCT07822334. Roche’s placebo-controlled RO7830698 study now lists recruiting, with 104 planned participants across healthy-volunteer single-dose and COPD multiple-dose portions. Primary outcomes are adverse events and dose-limiting events, with approximately 50- and 44-week windows.

The title says Phase 1, while structured registry fields say Phase 1/2; that discrepancy is retained rather than silently promoted to later-stage efficacy. The registry still calls October 20 an estimated start, so recruitment does not confirm first dosing. No patient benefit, harms rates, target-mechanism detail or U.S. COPD approval is established for this code. Primary/final completion estimates are October 11, 2028 / June 20, 2029.

Sources: Source 1.

Coverage and remaining gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (155 records). October 23 extended discovery through October 21–23 (25 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal-source coverage: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete.

Full coverage record.

Focused update — 2026-10-16

ENHANCE-3 registers a large COPD exacerbation trial

First posted October 15 — NCT07874815. Merck’s ENHANCE-3 (MK-5884-031/RPL554) plans 2,136 adults with COPD at elevated exacerbation risk. Participants receive twice-daily nebulized ensifentrine or matched placebo, alongside standard inhaler treatment. The primary outcome is the annualized rate of adjudicated moderate/severe exacerbations over 52 weeks; lung function, quality of life and harms are also assessed.

Status: Not yet recruiting; October 23, 2026 start and April 29, 2029 primary/final completion are estimates. No new results or mortality benefit.

U.S. context: Ensifentrine’s Ohtuvayre formulation was approved June 26, 2024 for maintenance treatment of adult COPD. That existing use is separate from the result of this new trial; it is not an acute rescue treatment.

Sources: Source 1; Source 2.

AERIFY-1 posts detailed tables; itepekimab remains discontinued

New registry disclosure, not a new topline — NCT04701983. October 15 tables supplement the May 2025 announcement. Phase 3 AERIFY-1 randomized 1,127 former smokers with COPD. In the order every-two-week / every-four-week / placebo, efficacy denominators are 375/377/375; adjusted moderate/severe exacerbation rates are 0.650/0.708/0.891 per participant-year. Active/placebo rate ratios are 0.729 (95% CI 0.598–0.890), p=.0019, and 0.795 (0.654–0.966), p=.0213. Both pass the prespecified ordered primary tests. These are recurrent-event rates, not absolute patient-risk reductions.

Safety uses 374/377/374 treated participants: serious treatment-emergent events 68/72/82, treatment stops for adverse events 9/11/14. AE follow-up extends approximately 58 or 78 weeks depending on extension entry; it is not uniformly 52 weeks. All-cause deaths 5/4/9 use still longer, unequal follow-up, potentially 242 weeks, and do not establish mortality benefit or treatment causation.

Context/U.S.: AERIFY-2 failed its primary endpoint; itepekimab development was discontinued in July 2026. These newly posted tables do not reopen the program or establish approval.

Sources: Source 1; Source 2; Source 3; Source 4.

ALIENTO posts detailed efficacy and safety tables

Registry disclosure October 16 — NCT05037929. ALIENTO’s topline dates to July 2025 and its Lancet paper to May 18, 2026. This is Phase 2b, not Phase 3. Among 433/437/431 initial-phase participants (every-two-week/every-four-week/placebo), adjusted 52-week moderate/severe exacerbation rates are 1.110/1.222/1.315 per patient-year. Registry active/placebo rate ratios are 0.845 (95% CI 0.715–0.998), p=.0468, and 0.930 (0.789–1.095), p=.3829. The first primary test passes, the second fails; a failed low-eosinophil secondary gate limits later confirmatory claims.

Safety spans 449/442/442 actually treated participants, including later enrollment and assignment differences, for up to 98.1 weeks. Any AEs: 367/370/386; serious AEs: 111/126/137; all-cause deaths: 13/11/16. These are descriptive, not uniformly 52-week risks or evidence of mortality benefit.

Context/U.S.: The Lancet abstract reports p=.049; the small source discrepancy is unexplained, so it is retained separately. Companion Phase 3 ARNASA failed its primary endpoint. Astegolimab remains investigational; no verified U.S. approval or filing date. Extension completion is estimated June 30, 2027, not an FDA decision date.

Sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 153 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. COPD SAPs and primary disclosure history were independently checked. ALIENTO registry versus paper p-value differs slightly without a verified explanation; full Lancet text remains inaccessible.

Informal-source coverage: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence.

Full coverage record.

Focused update — 2026-10-13

SUPRA-COPD will test urolithin A alongside pulmonary rehabilitation

First posted October 13, 2026. NCT07871357 plans a masked randomized phase 2 study in 198 adults with COPD, comparing urolithin A 1,000 mg daily with placebo during eight weeks of pulmonary rehabilitation. Primary constant-work-rate exercise endurance differs from secondary six-minute walk distance, quadriceps strength, quality of life and DXA body composition. The adaptive sample-size re-estimation at 50% recruitment may change the final planned sample.

Status/limits/safety/U.S.: Not yet recruiting; no results or harms rates. A mitophagy rationale does not demonstrate improved breathing, reduced exacerbations or longer life. Supplement marketing is not a COPD drug approval. Timing: November 2026 estimated start; December 2029 estimated primary/final completion. No public readout date.

Sources: Source 1.

Inhaled cell therapy registers an early COPD safety study

First posted October 13, 2026. SMSbiotech’s NCT07871890 plans 125 adults with moderate/severe COPD in sequential open-label phase 1b/2a safety and expansion cohorts. The protocol administers sponsor-named small mobile stem cells by nebulizer on days 1, 3 and 6, with the same regimen in both cohorts. Safety, laboratory/ECG/vital-sign abnormalities, lung-function changes and inhalation/hypersensitivity reactions are primary assessments; there is no placebo arm.

Status/limits/U.S.: Not yet recruiting despite an October 1 estimated start. No efficacy or safety results, independent comparative evidence or verified U.S. marketing approval. Registration alone does not substantiate regeneration or authorize commercial treatment. Timing: October 2027 primary and December 2027 final completion remain month-precision estimates, not readout promises.

Sources: Source 1.

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 135 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. No fuller acute-COPD absolute effect/CI/harms or verified VIASKIN FDA action date recovered; broad food/sinus coverage incomplete.

Informal-source coverage: Targeted rademikibart/VIASKIN/asthma Reddit and podcast searches mainly returned known topline/submission reposts and patient experience. No fresh distinct development claim selected; full talk/transcript coverage incomplete.

Full coverage record.

Focused update — 2026-10-09

Tilrekimig registers a recruiting phase 3 severe-asthma trial

First posted October 9, 2026; registry-reported actual start September 30. NCT07869043 plans 1,100 adults and adolescents with severe asthma, randomized and masked to subcutaneous tilrekimig/PF-07275315 or placebo alongside background care. Its primary endpoint is annualized protocol-defined exacerbations over fifty-two weeks; lung function, symptom control, quality of life and remission are distinct secondary measures.

Mechanism/evidence limits: Pfizer describes a trispecific antibody against IL-4, IL-13 and TSLP. Its October 1 atopic-dermatitis report concerns a different indication and cannot establish asthma efficacy. No results or numerical safety rates are posted for this phase 3 trial; recruitment is not demonstrated benefit.

U.S./next: Investigational. Estimated primary completion June 7, 2029, final August 30, 2029; no announced readout date.

Primary registry; October 1 sponsor mechanism/context.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (131 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No fuller rademikibart acute-COPD absolute-count/CI/harms table or verified VIASKIN filing acceptance/action date recovered. Food/environmental allergy and sinus literature remain incomplete; no approval inferred from submission.

Informal-source coverage: Reddit rademikibart/VIASKIN and allergy podcast discovery mainly surfaced known sponsor readout/submission reposts and personal treatment experience. No independent new development rumor selected. Original conference audio and broader seasonal/sinus informal survey remain unappraised.

Full coverage record.

Focused update — 2026-10-06

Small peanut-immunotherapy trial misses abatacept’s primary immune endpoint

Source date: September 30, 2026 publication; recovered October 6. Evidence: Phase 2a randomized trial, primary abstract; full paper not appraised.

Fourteen participants aged 14–50 with severe peanut allergy were assigned 1:1 to abatacept or placebo added to 24 weeks of oral immunotherapy, then 12 weeks of immunotherapy alone. The primary relative peanut-specific/total IgE-ratio change was 48.2% versus 87.9%, p=.26. Median minimal reactive doses were similar (3,000 mg) after four weeks of avoidance. Overall adverse-event counts averaged 5.9 versus 10 per participant (p=.006).

Limits/safety: Very small trial; the primary biomarker hypothesis was not supported. Exploratory tolerability does not establish lasting food-allergy remission or a favorable long-term immunosuppression tradeoff. Separate symptom reactions, laboratory markers and sustained tolerance. Trial identifier and detailed safety tables were not recovered.

U.S./next: This paper does not establish an abatacept food-allergy indication or guideline change. Larger controlled confirmation would be needed; no date announced.

Primary abstract; publication DOI.

Adolescent asthma study registers a triple-inhaler comparison

Source date: October 5, 2026 first posting. Evidence: NCT07858123, randomized masked phase 3 study, not yet recruiting.

Seven hundred planned adolescents with asthma receive beclometasone/formoterol/glycopyrronium (CHF5993) or fluticasone/salmeterol (Seretide). Primary endpoint is adjusted change in pre-dose FEV1 at week 26.

Limits/safety/U.S.: No results or adverse-event rates; improved spirometry would not itself establish durable remission or fewer serious exacerbations. Registration does not establish U.S. authorization for this population/formulation.

Next: November 16, 2026 estimated start; June 26, 2030 estimated primary/final completion.

Primary registry.

Coverage: Official registry overlap discovery

Remaining gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 120 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. No fuller rademikibart absolute event/safety table or verified VIASKIN filing-acceptance target recovered. Sinus-disease and guideline survey incomplete.

Informal-source coverage: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Full coverage record.

Focused update — 2026-10-02

Rademikibart acute-COPD phase 2 reports fewer treatment failures

Source/event date: 2026-09-30. Evidence: Sponsor-only preliminary randomized phase 2 topline.

Seabreeze STAT COPD (NCT06940154) randomized 159 adults with acute COPD exacerbation and eosinophils ≥300/µL to one rademikibart injection or placebo alongside standard care. Sponsor reports 81% relative reduction in 28-day treatment failure (p=0.0122), a composite of death, COPD rehospitalization/emergency or unscheduled visits, and treatment intensification. Moderate/severe exacerbations fell 85% relatively (p=0.030). Absolute counts and confidence intervals were undisclosed. Week-4 FEV1 improved 70 mL versus placebo, without statistical significance (p=0.1607); key secondary week-1 results were not reported. Adverse and serious adverse events were qualitatively described as lower, without a numerical table. Eight-week follow-up cannot establish long-term safety. Registry says completed (actual n159, final August 26), without posted results. This COPD result is distinct from the earlier asthma primary-endpoint miss. Rademikibart remains investigational. Sponsor.

Next milestone: Sponsor plans FDA discussions on phase 3; full efficacy/safety tables and meeting timing remain undated.

Source 1; Source 2.

VIASKIN Peanut BLA submitted for children aged 4–7

Source/event date: 2026-09-29. Evidence: Sponsor-reported regulatory submission.

DBV announced VIASKIN Peanut BLA submission for peanut-allergic children aged 4–7 on September 29 at 18:29 Eastern. Priority Review was requested; FDA acceptance or granted Priority Review has not been established. The dossier uses VITESSE (NCT05741476), a randomized double-blind 2:1 patch-versus-placebo trial of 654 children over 12 months. This is a filing milestone, not new efficacy, approval, cure, or evidence that unrestricted peanut consumption is safe. No VIASKIN product is approved, according to the sponsor. The separate toddler group is not included in this application. Sponsor.

Next milestone: FDA filing acceptance, review designation and action date remain unverified.

Source 1; Source 2.

Coverage: rademikibart Seabreeze STAT COPD September 30 2026 results; DBV VIASKIN Peanut BLA September 29 2026; NCT06940154 NCT05741476 current registry; rademikibart VIASKIN Reddit September 2026.

Remaining gaps: COPD release omits absolute event counts, confidence intervals, quantitative harms and key secondary week-1 FEV1; no registry result tables. VITESSE registry January update predates actual n654. Submission does not equal FDA acceptance or granted Priority Review. Broad COPD/asthma/sinus/allergy discovery and informal transcript coverage incomplete.

Informal-source coverage: No additional attributable signal selected in this focused search; No independent noteworthy rumor selected; two sponsor forecast milestones now formally reported.

Next update: VIASKIN filing acceptance/action date and COPD phase 3 alignment remain undated. Requested Priority Review is not granted Priority Review.

Full coverage record.

Focused update — 2026-09-29

Related findings:

• Engineered-phage STEPS-CF trial receives conditional UK authorization.

Coverage: September 6–29 overlap, rademikibart COPD/VIASKIN filing and new airway trial discovery; cross-link STEPS-CF.

Remaining gaps: September COPD readout and Q3 VIASKIN filing not verified complete; neither window has elapsed on September29. Environmental/food-allergy, sinus and full ERS source/registry census incomplete.

Informal-source coverage: Reddit investor posts repeat September CNTB forecasts; DBV secondary conference transcript echoes filing plans. No original recording establishing a completed filing/result was appraised.

Full coverage record.

Focused update — 2026-09-27

No additional finding was verified in the reviewed sources. Coverage remains partial; this is not a full-topic “no news” conclusion.

Coverage: Rademikibart asthma and VIASKIN VITESSE registry snapshots; targeted COPD readout/BLA and ERS follow-up discovery.

Remaining gaps: Current DBV press-page access failed; no new BLA acceptance or completed filing verified. Rademikibart COPD September/Q3 readout window remains unconfirmed and has not elapsed on September 27. Full ERS abstracts, food/environmental allergy and all relevant registries not appraised. Stale VITESSE registry enrollment should not replace sponsor actual trial counts.

Informal-source coverage: Reddit investor anticipation and a secondary DBV transcript surfaced; underlying conference recording not reviewed. Forecast repetition is not evidence of results or regulatory action.

Full coverage record.

Focused update — 2026-09-22

Acute-asthma rademikibart study misses its primary endpoint

Source date: 2026-09-15. Event date: 2026-09-15. Evidence: Sponsor topline; overlap-window finding.

Seabreeze STAT Asthma missed statistical significance on 28-day treatment failure despite a reported 66% relative reduction (p=.153). The day-7 lung-function secondary endpoint improved. NCT06940141 randomized 160 patients with acute asthma exacerbation and type-2 inflammation to a single 600-mg dose plus standard care (79) or placebo plus standard care (81). FEV1 improved 250 versus 120 mL, a 130-mL difference (p=.023).

Limitations: The sponsor’s positive headline does not change the primary-endpoint miss. FEV1 is not interchangeable with fewer hospitalizations or treatment failures. Absolute primary-event counts and uncertainty intervals were not supplied in the release.

Safety: Serious adverse events: 1 active versus 3 placebo; no adverse-event discontinuations reported. Short follow-up cannot establish long-term safety.

U.S. status: Investigational; no U.S. approval.

Next milestone: COPD topline remains sponsor-forecast for September 2026; proposed phase 3 design and FDA alignment are not established.

Connect September 15 release; Seabreeze STAT Asthma registry.

Related findings:

• ARIKAYCE broader-use application gets priority review.

Coverage: Recovered September15 rademikibart primary-endpoint miss; verified original registry and VIASKIN filing forecast.

Remaining gaps: Rademikibart exploratory-subgroup full paper inaccessible; all ERS abstracts/environmental-allergy studies not fully reviewed. No original COPD topline or actual VIASKIN BLA submission verified.

Informal-source coverage: September8 Reddit discussion anticipated September readouts and correctly distinguished FEV1 from primary treatment failure; later actual result recorded separately, not rumor confirmation of efficacy. Bio Report190 Sept2 describes preclinical allergy CAR-T work, no verified human trial. https://www.reddit.com/r/biotech_stocks/comments/1waqxwm/cntb_has_two_phase_2_results_coming_this_month/

Full coverage record.

Next update: Rademikibart COPD topline and VIASKIN filing remain September/Q3 2026 sponsor forecasts; no approval or COPD result inferred.

Focused update — 2026-09-18

Inhaled RNA interference reaches human lung target-engagement evidence

Source date: 2026-09-09. Evidence: Peer-reviewed randomized phase 1/2a study.

ARO-RAGE reduced its lung inflammatory target in early human research; fewer asthma attacks or COPD benefit have not been demonstrated. NCT05276570 studied healthy volunteers and mild-to-moderate type-2 asthma. The published cohorts include 58 treated healthy volunteers and 19 treated asthma patients, with 29 placebo participants. The study focused on safety and target engagement; pulmonary-function measures were safety assessments, not powered efficacy tests.

Limitations: The registry lists 127 overall participants, while the published cohorts total 106; the abstract active-treatment counts must not be represented as all randomized participants. No clinical-outcome benefit is inferred from soluble-RAGE reduction.

Safety: Headache and respiratory infections were common. COVID-19 occurred in 14/58 treated healthy volunteers versus 2/23 placebo. One delayed pre-eclampsia serious event was assessed unrelated; no asthma serious events. Small cohorts cannot settle uncommon harms.

U.S. status: Investigational inhaled siRNA; no U.S. approval.

Next milestone: Separate phase 2a NCT07241546 is recruiting (target 36); primary completion December 2027 is a registry estimate, not a promised readout.

Nature Medicine, September 9; Original full text; Next study.

Coverage: ARO-RAGE original full text and both registry records; tozorakimab/VIASKIN and new human airway searches. This is a focused review, not a complete re-review of every program.

Remaining gaps: VIASKIN Q3 filing remains a forecast in source checked; full ERS abstracts, rademikibart exploratory subgroups and broader environmental-allergy trials remain partial.

Informal-source coverage: Reddit/podcast and investor remarks searched; Sept18 stories repeated earlier filing plans, not verified submission. Original September investor recording not appraised.

Full coverage record.

Next expected updates: Tozorakimab’s US COPD decision is anticipated in Q1 2027, per the September 8 sponsor announcement; no exact day was verified. VIASKIN Peanut filing in Q3 2026 for ages 4–7, and conditionally H2 2026 for ages 1–3, remain sponsor forecasts, not confirmed filings or FDA decision dates.

Food-allergy interpretation and safety. OUtMATCH Stage 2 was reported in a conference journal supplement, summarized by NIH; completer-only response proportions were similar. Omalizumab carries anaphylaxis risk and is not emergency treatment. VIASKIN's December 16, 2025 sponsor topline reported mostly local skin reactions, with treatment-related anaphylaxis in 0.5% (two children); its challenge-response difference was 31.8 percentage points (95% CI 24.5–39.0). The older H1 2026 filing forecast was superseded by Q3 guidance. VIASKIN topline.

Airway limitations and negative findings. Depemokimab's less frequent dosing does not establish equivalence when switching from another successful biologic: GSK reported that the NIMBLE switching study failed its statistical non-inferiority criterion. Monitor hypersensitivity and helminth-infection precautions. GSK Q1 2026 update. For COPD, MATINEE's benefits concern exacerbations on triple inhaled therapy; adverse-event incidence was similar between groups. Itepekimab development was discontinued in COPD, CRSwNP and sinus disease without polyps according to the July 2026 filing. Retain that outcome when scouting new IL-33/TSLP and other programs rather than resurrecting obsolete trial forecasts.

Dated history

2026-10-02 — Scheduled focused review

2 newly recorded findings or milestones; primary evidence, uncertainty and incomplete coverage are detailed above and in the run record. Full-topic successful-check dates remain unchanged.

• 2026-09-29: 0 sourced entries, 1 cross-topic links and 0 informal-source checks. Coverage and gaps.

• 2026-09-27: 0 sourced entries and 0 cross-topic links from a focused scheduled check. Coverage and remaining gaps.

• 2026-09-22: Focused scheduled research retry; 1 sourced entries and 1 cross-topic links. Coverage and gaps.

2026-09-14 — Focused ad-hoc update

Tozorakimab reduces COPD exacerbations in two phase 3 trials; US review underway. Full OBERON and TITANIA results evaluated tozorakimab 300 mg every four weeks for 52 weeks in COPD with prior exacerbations despite inhaled maintenance therapy. In the primary former-smoker population, annualized moderate/severe exacerbations were 1.34 versus 1.90 in OBERON (rate ratio 0.71, 95% CI 0.57–0.88) and 1.37 versus 2.07 in TITANIA (0.66, 0.55–0.80). Overall adverse-event frequencies were 70.4% versus 77.2% and 80.1% versus 79.8%, respectively. These are exacerbation outcomes, not mortality evidence. AstraZeneca also reported FDA Priority Review of the COPD application, with an anticipated decision during Q1 2027. Tozorakimab remains investigational. NEJM article, September 8. Original abstract record. AstraZeneca, September 8.

Next: Anticipated FDA decision during Q1 2027; no exact PDUFA day was established. The September 8 full results add information beyond the earlier March topline.

Source and coverage limits: The journal abstract was retrieved through Europe PMC after direct publisher access failed. Its treatment-group counts differ from the total randomized count in the sponsor release; no total enrollment figure is asserted here pending reconciliation. DBV filing forecasts, other ERS data and respiratory/food-allergy programs were searched selectively, but the full conference data, all major sponsors and trial-registry changes were not comprehensively reviewed. Informal searches did not establish a new substantiated rumor or a causal treatment conclusion from observational semaglutide discussion. This is a partial refresh.

• September 13, 2026 — selective baseline completed: Checked NIH/FDA records, original human-study abstracts, trial registration and dated sponsor/SEC updates, including June–September coverage. Established separate food, environmental, asthma, COPD and sinus scopes; captured revised VIASKIN filing windows and itepekimab discontinuation. Some evidence remains sponsor-only; no comprehensive informal-source search or exhaustive program census was performed. No rumor was added. This is a new-topic baseline, not an all-topic monitoring run.

September 13 scope-expansion record.

2026-09-18 — Scheduled focused review

ARO-RAGE original full text and both registry records; tozorakimab/VIASKIN and new human airway searches. Original event dates, safety and limitations are retained in the September 18 update above. The complete-topic successful-check date was not advanced because the listed gaps remain. Run record.